Table 4. Allele combination analysis of microRNA polymorphisms in ischemic stroke patients and controls.

Allele combination		Control	Stroke	Control vs Stroke			LAA	Control vs LAA subtype			SVO	Control vs SVO subtype
		(n = 400)	(n = 523)	AOR (95% CI)a	P a	FDR-P a	(n = 206)	AOR (95% CI)b	P b	FDR-P b	(n = 141)	AOR (95% CI)c	P c	FDR-P c
miR-130b/200b/495	T-T-A	0.257	0.261	1.000 (reference)			0.260	1.000 (reference)			0.233	1.000 (reference)
	T-T-C	0.248	0.235	0.896 (0.682–1.176)	0.427	0.744	0.265	1.056 (0.748–1.491)	0.755	0.881	0.224	0.950 (0.623–1.448)	0.810	0.946
	T-C-A	0.107	0.126	0.994 (0.676–1.462)	0.977	0.977	0.117	0.741 (0.432–1.269)	0.275	0.751	0.121	1.357 (0.784–2.348)	0.275	0.868
	T-C-C	0.138	0.117	0.855 (0.625–1.170)	0.327	0.744	0.117	0.908 (0.604–1.364)	0.642	0.881	0.142	1.016 (0.639–1.617)	0.946	0.946
	C-T-A	0.091	0.072	0.865 (0.548–1.363)	0.531	0.744	0.069	0.901 (0.489–1.657)	0.736	0.881	0.090	0.960 (0.485–1.900)	0.906	0.946
	C-T-C	0.060	0.113	1.368 (0.925–2.024)	0.117	0.744	0.103	1.292 (0.778–2.147)	0.322	0.751	0.106	1.482 (0.850–2.587)	0.166	0.868
	C-C-A	0.045	0.045	0.791 (0.451–1.388)	0.414	0.744	0.044	1.011 (0.504–2.031)	0.975	0.975	0.045	0.729 (0.293–1.813)	0.496	0.868
	C-C-C	0.054	0.032	0.926 (0.650–1.320)	0.672	0.784	0.025	0.766 (0.469–1.249)	0.285	0.751	0.040	1.249 (0.749–2.081)	0.395	0.868
miR-130b/200b	T-T	0.504	0.497	1.000 (reference)			0.527	1.000 (reference)			0.457	1.000 (reference)
	T-C	0.246	0.241	0.942 (0.734–1.208)	0.637	0.637	0.233	0.822 (0.591–1.143)	0.244	0.450	0.263	1.185 (0.822–1.709)	0.362	0.533
	C-T	0.152	0.184	1.178 (0.873–1.591)	0.283	0.637	0.170	1.096 (0.742–1.619)	0.646	0.648	0.195	1.289 (0.831–1.999)	0.256	0.533
	C-C	0.098	0.078	0.923 (0.684–1.247)	0.602	0.637	0.070	0.809 (0.542–1.207)	0.300	0.450	0.085	1.153 (0.738–1.801)	0.533	0.533
miR-130b/495	T-A	0.364	0.385	1.000 (reference)			0.377	1.000 (reference)			0.354	1.000 (reference)
	T-C	0.386	0.353	0.883 (0.705–1.105)	0.276	0.486	0.383	1.058 (0.790–1.416)	0.705	0.951	0.366	0.908 (0.649–1.271)	0.575	0.575
	C-A	0.136	0.118	0.832 (0.577–1.199)	0.324	0.486	0.114	0.985 (0.611–1.587)	0.951	0.951	0.136	0.815 (0.469–1.416)	0.467	0.575
	C-C	0.114	0.144	1.099 (0.832–1.451)	0.509	0.509	0.127	1.036 (0.712–1.509)	0.852	0.951	0.145	1.227 (0.825–1.823)	0.312	0.575
miR-200b/495	T-A	0.348	0.333	1.000 (reference)			0.327	1.000 (reference)			0.326	1.000 (reference)
	T-C	0.308	0.348	1.027 (0.808–1.306)	0.827	0.827	0.370	1.127 (0.829–1.532)	0.445	0.445	0.327	1.082 (0.754–1.553)	0.669	0.669
	C-A	0.152	0.170	0.948 (0.681–1.320)	0.753	0.827	0.163	0.835 (0.536–1.299)	0.423	0.445	0.164	1.130 (0.699–1.827)	0.618	0.669
	C-C	0.192	0.150	0.903 (0.700–1.165)	0.434	0.827	0.140	0.867 (0.618–1.215)	0.406	0.445	0.184	1.100 (0.759–1.594)	0.616	0.669

Data are prevalence, AOR (95% CI), and P-value for each allele combination of microRNA polymorphism. Adjustment was performed for sex, age, hypertension, diabetes mellitus, hyperlipidemia, and current smoking. Results for the cardioembolism subtype were omitted due to the small sample size and non-significant finding. AOR = adjusted odds ratio, CI = confidence interval, LAA = large-artery atherosclerosis, SVO = small-vessel occlusion, OR = odds ratio, FDR = false discovered rate.

^a statistics for ischemic stroke compared with controls.

^b statistics for LAA compared with controls.

^c statistics for SVO compared with controls.